1. Introduction {#sec1}
===============

Tuberculosis (TB) still continues to be a big public health problem worldwide. It is the second leading cause of death from all infectious diseases globally. Tuberculosis kills an estimate of 1.3 million people every year worldwide \[[@B1]\]. It is also one of the most serious public health challenges in Ethiopia. Ethiopia is ranked second after Nigeria and seventh globally among the 22 countries with high TB burden \[[@B2]\].

The main new barrier that challenges the control of TB is high burden of multidrug-resistant TB (MDR-TB). MDR-TB is a man-made problem due to poor management and quality of antituberculosis drugs. Thus, MDR-TB can be minimized by making tight identification of its predictors \[[@B1]\]. The major contributing factor identified for the spread of MDR-TB is poor infection control \[[@B1]\]. MDR-TB kills an estimate of 110,000 individuals every year and nearly half million new cases of MDR-TB emerge every year. Among the newly emerging MDR-TB cases, only 3% get serious treatment globally \[[@B3]\].

In 2008, there were 440,000 new MDR-TB cases and 150,000 deaths worldwide \[[@B4]\]. According to the Ethiopian national TB drug resistance surveillance reported, 2.3% of new TB cases and 17.8% of previously treated TB cases were estimated to have MDR-TB \[[@B5]\]. In Africa, there was a report of 69,000 MDR-TB cases \[[@B4]\]. Ethiopia ranked 15th with new cases of MDR-TB each year and is one of the 27 countries with high MDR-TB burden \[[@B3]\]. Even if MDR-TB is highly prevalent in retreated TB cases, the prevalence of MDR-TB in newly diagnosed TB patients has been reported to be 2.8% \[[@B1], [@B6]\]. There are a number of published studies on MDR-TB available worldwide. However, accurate data on MDR-TB in Ethiopia is scarce. This review provides an updated and comprehensive status of the MDR-TB epidemics in Ethiopia. Thus, the main aim of this review was to assess the current prevalence of MDR-TB and factors associated with MDR-TB in Ethiopia.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

Studies that estimated rate of MDR-TB and/or identified factors associated with MDR-TB were systematically reviewed. All studies that were published up to 2016 were critically reviewed. We used PubMed search engines and Google Scholar by using medical subject titles MDR-TB, associated factors, and antituberculosis drug resistance. The references of included articles were appropriately scanned to identify additional articles of interest and we used HINARI to access articles without payment.

2.2. Selection of Studies {#sec2.2}
-------------------------

We used the following criteria to include articles in our study:Articles with clear objective and methodologyAll articles published up to September 2016Articles that address prevalence of MDR-TB and/or associated factorsArticles published in English languageArticles with their full texts obtained

2.3. Data Collection Tool and Procedure {#sec2.3}
---------------------------------------

Data was collected from the articles through development of data collection checklist. The data collection checklist was pretested in 5 randomly selected articles and it was amended accordingly. The checklist included title, authors\' names, year of publication, study time, study design, sample size, rate of MDR-TB, predictors of MDR-TB, and study setting. The prevalence of MDR-TB and/or associated factors reported in all the selected studies was tallied and assessed.

2.4. Operational Definitions {#sec2.4}
----------------------------

The following definitions related to drug resistance were used \[[@B7]\]:MDR-TB: TB caused by strains of*Mycobacterium tuberculosis* which are resistant to at least Isoniazid (INH) and Rifampicin (RMP)

3. Results {#sec3}
==========

In our electronic search, 546 citations were depicted. Among the total 546 articles described, 500 were excluded by reviewing their titles, 14 were excluded following full-text review, and 10 were excluded because the title did not show results directly related to our topic. Finally, a total of 22 articles that met eligibility criteria were included in the review article ([Figure 1](#fig1){ref-type="fig"}). Among the total 22 articles that met inclusion criteria, 15 studies only reported the prevalence of MDR-TB and they did not asses the factors that were associated with MDR-TB. On the other hand, seven articles reported factors associated with MDR-TB. Among the 7 articles that assessed predictors of MDR-TB, two articles reported findings exclusively focusing on predictors of MDR-TB. They did not report prevalence of MDR-TB, because all the patients that were included in the study represented exclusively MDR-TB cases.

3.1. Prevalence of MDR-TB {#sec3.1}
-------------------------

In our review, we assessed the overall prevalence of MDR-TB among all TB cases by adding all the number of patients with MDR-TB and dividing it by the total number of studied patients. The total number of patients studied in the review was found to be 3849. Among the total patients studied, 527 had MDR-TB. Thus, the overall prevalence of MDR-TB in this review was found to be 1.4%. The studies were conducted during the period of 1994--2014 from different territories of the country \[[@B7]--[@B26]\] ([Table 1](#tab1){ref-type="table"}).

The maximum peak rate of MDR-TB recorded in the country was 46.3% in 2010 \[[@B16]\] and the minimum rate of MDR-TB was 0% \[[@B7]\]. The average mean rate of MDR-TB was 12.6 ± 15.9%, ranging from 0 to 46.3% \[[@B7]--[@B26]\]. In 2006 and 2005, respectively, second (42.9%) \[[@B12]\] and third (38.3%) maximum peaks of MDR-TB prevalence were reported \[[@B11]\]. Starting from 2011, a significant decline in rate of MDR-TB was found, despite a 33.2% record of MDR-TB in 2014 \[[@B18]--[@B20], [@B22], [@B23], [@B25], [@B26]\] ([Table 1](#tab1){ref-type="table"}). A zero rate of MDR-TB was recorded in Addis Ababa in 1997 \[[@B7]\]. Generally, there were heterogeneous distribution and prevalence rate of MDR-TB report in the country according to the reviewed studies [Figure 2](#fig2){ref-type="fig"}.

3.2. Risk Factors Associated with MDR-TB {#sec3.2}
----------------------------------------

Our review found that the most commonly reported predictor of MDR-TB was previous exposure to anti-TB treatment \[[@B12], [@B14], [@B15]\]. On the contrary, Biadglegne et al. in 2014 showed that there was a negative association between MDR-TB and previous exposure to anti-TB treatment \[[@B19]\]. In the study, newly treated TB cases harbor patients from development of MDR-TB \[[@B19]\]. Another risk factor that was found to be a predictor of MDR-TB was HIV disease \[[@B13], [@B17]\]. Being male has also been identified to be a predictor of MDR-TB in Ethiopia \[[@B13], [@B16], [@B19]\]. The factors that were associated with MDR-TB vary from study time to study time and from study place to study place. The different factors that were associated with MDR-TB are described in [Table 2](#tab2){ref-type="table"}.

4. Discussion {#sec4}
=============

This study reviewed the prevalence rate of MDR-TB and the different factors associated with MDR-TB in Ethiopia. In the review, a total of 22 articles that assess prevalence of MDR-TB and/or factors associated with MDR-TB were reviewed. The papers were conducted starting from 1994 to 2014. The prevalence rate found as well as the factors associated with MDR-TB was found to be frequently heterogeneous with respect to geographical areas and study periods.

This review study found prevalence of MDR-TB to be 1.4% among all TB cases with an average mean rate of 12.6 ± 15.9%, ranging from 0 to 46.3% \[[@B7]--[@B26]\]. This finding is lower as compared to the 2017 WHO anti-TB drug resistance surveillance data report, which showed that 4.1% of new and 19% of previously treated TB cases in the world are estimated to have Rifampicin-resistant or multidrug-resistant tuberculosis (RR-TB/MDR-TB) \[[@B30]\]. This might be due to study design difference, where 2017 MDR-TB WHO report\'s estimated prevalence was for either Rifampicin resistance or Rifampicin and Isoniazid resistance. However, in our study, resistance to both Rifampicin and Isoniazid was declared as MDR-TB. Moreover, 2017 WHO MDR-TB surveillance report estimated the prevalence of MDR-TB in new TB cases and previously treated cases separately. In our study, we could not estimate prevalence of MDR-TB in new TB cases and retreated TB cases separately due to reported variation of the published papers. Moreover, estimates presented by global control programs are based on samples from government centers comprising potentially susceptible populations or populations where the infection appearance or recurrence is monitored regularly and treated optimally. Therefore, estimates generated from an analysis of these samples may not be a true representation of the TB population in the real world \[[@B31], [@B32]\]. An Indian systematic review also found MDR-TB prevalence of 23.3% among all TB cases \[[@B33]\]. This is quite higher when compared to our study. This might be due to variation in patient group studied. The healthcare setup, MDR-TB detection, and the population socioeconomic status variation between the two countries might contribute to the discrepancy.

The lowest record of MDR-TB was in 1997 \[[@B7]\], whereas the highest record of MDR-TB was in 2010 \[[@B16]\]. This highest record of MDR-TB in 2010 as compared to earlier periods might be due to previous antituberculosis exposure of TB cases. Starting from 2010, relatively significant decline in MDR-TB was reported \[[@B18]--[@B20], [@B22], [@B23], [@B25], [@B26]\]. This relative decline in MDR-TB could be due to great emphasis given for quality provision of TB control and diagnostic parameters in the country. The country achieved not only TB control but also MDR-TB treatment of ≥75% in 2015, making the country one of the three countries with high MDR-TB burden which achieved MDR-TB treatment of ≥75% \[[@B27]\]. This showed that the control of TB and treatment of MDR-TB are escalating from time to time in Ethiopia. Despite improvement in incidence of MDR-TB, this finding showed the spread of MDR-TB and the local control measures for the prevention of MDR-TB are still unsatisfactory.

The commonly identified risk factor of MDR-TB in this review was previous exposure of patients to antituberculosis treatment \[[@B12], [@B14], [@B15], [@B24]--[@B29], [@B27]\]. Previous antituberculosis treatment exposure is also a common risk factor for MDR-TB in many other countries like India, Spain, Iran, Portugal, Europe, and other east African countries \[[@B34]--[@B41]\]. The WHO report in 2013 also confirmed that the highest prevalence of MDR-TB among new and previously treated TB cases was 3.6% and 20.2%, respectively, which is higher in previously treated patients. The high association of previous TB treatment and MDR-TB might be explained due to inappropriate chemotherapy regimens, inadequate or irregular drug supply, unsatisfactory patient or clinician compliance, lack of supervision of treatment, and absence of infection control measures in hospitals \[[@B37]\]. Another factor that was commonly identified as a risk factor was HIV/AIDS \[[@B13]--[@B15], [@B17], [@B19]\]. In addition, alcohol use and treatment failure also were found to be predictors of MDR-TB in Ethiopia \[[@B24], [@B29]\]. This is in congruence with the finding depicted from Spain \[[@B42]\]. Being male and young age were also other factors that were described as determinant factors of MDR-TB in Ethiopia \[[@B16], [@B19], [@B24]\]. However, there were also a number of reports from the country (Ethiopia) which contradict the finding \[[@B12], [@B14], [@B15]\]. The discrepancy could be due to difference in study subjects, sample size, and study variables studied.

In this study, there are some limitations. The number of articles that were reviewed was very small due to scarcity of published articles from the country. In the reviewed articles, the study designs used were heterogeneous, which could bias the finding. There was also a discrepancy in reporting of findings. Some studies only studied rate of MDR-TB; other studies studied only factors associated with MDR-TB. In this review study, there was a heterogeneous report of the articles outcome.

5. Conclusion {#sec5}
=============

Even if the incidence of MDR-TB was declined relatively, MDR-TB prevalence and distribution is still a serious public health problem in the country. Prior history of antituberculosis treatment was the most commonly identified risk factor for MDR-TB. Thus, improving TB follow-up strategy in association with provision of strong primary TB as well as MDR-TB treatment could improve TB control in Ethiopia.
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###### 

Prevalence of MDR-TB in Ethiopia in the period of 1994--2014.

  Author                         Number of subjects   Study time/period   MDR-TB
  ------------------------------ -------------------- ------------------- -------------
  Dmissie et al. \[[@B7]\]                                                 
   New cases                     167                  1994                2 (1.2%)
   Retreated cases               NS                                       NS
   Total                         167                                      2 (1.2%)
  Ahmed and Hoffner \[[@B8]\]                                              
   New cases                     NS                   1996                NS
   Retreated cases               107                                      13 (12%)
   Total                         107                                      13 (12%)
  Bruchfeld et al. \[[@B9]\]                                               
   New  cases                    103                                      0
   Retreated cases               18                   1997                0
   Total                         121                                      0
  Eyob et al. \[[@B10]\]                                                   
   New cases                     73                                       2 (2.7%)
   Retreated cases               19                   2001                2 (10.5%)
   Not known                     2                                        1
   Total                         94                                       5 (5.3%)
  Dest et al. \[[@B11]\]                                                   
   New cases                     73                                       46 (38.3%)
   Retreated cases               NS                   2005                NS
   Total                         73                                       46 (38.3%)
  Agonafi et al. \[[@B12]\]                                                
   New cases                     44                                       1 (2.3%)
   Retreated cases               63                   2006                45 (71.4%)
   Total                         114                                      46 (42.9%)
  Yimer et al. \[[@B13]\]                                                  
   New cases                     93                                       1 (1%)
   Retreated cases               NS                   2008                NS
   Total                         93                                       1 (1%)
  Abebe et al. \[[@B14]\]                                                  
   New cases                     214                                      8 (4.2%)
   Retreated cases               46                   2009                5 (10.9%)
   Total                         260                                      13 (5%)
  Abate et al. \[[@B15]\]                                                  
   New cases                     NR                                       NR
   Retreated cases               NR                   2010                NR
   Total                         376                                      174 (46.3%)
  Abate et al. \[[@B16]\]                                                  
   New cases                     NR                                       NR
   Retreated cases               NR                   2010-2011           NR
   Total                         136                                      2 (1.5%)
  Tessema et al. \[[@B17]\]                                                
   New cases                     136                                      2 (1.5%)
   Retreated cases               NS                   2011                NS
   Total                         136                                      2 (1.5%)
  Hussein et al. \[[@B18]\]                                                
   New cases                     93                                       11 (11.7%)
   Retreated cases               9                    2011                1 (11.11%)
   Total                         102                                      12 (11.8%)
  Biadglegne et al. \[[@B19]\]                                             
   New cases                     212                  2012                1 (0.5%)
   Retreated cases               13                                       0
   Total                         225                                      2 (0.8%)
  Adane et al. \[[@B20]\]                                                  
   New cases                     77                                       1 (1.29%)
   Retreated cases               12                   2012                2 (18.66%)
   Total                         89                                       3 (3.37%)
  Nigus et al. \[[@B21]\]                                                  
   New cases                     NR                                       NR
   Retreated cases               NR                   2012-2013           NR
   Total                         606                                      93 (15.3%)
  Shegaw \[[@B22]\]                                                        
   New cases                     NR                                       NR
   Retreated cases               NR                   2012--2014          NR
   Total                         434                                      9 (2.1%)
  Seyoum et al. \[[@B23]\]                                                 
   New cases                     357                                      4 (1.1)
   Retreated cases               NS                   2013                NS
   Total                         357                                      4 (1.1%)
  Mulisa et al. \[[@B24]\]                                                 
   New cases                     NR                                       NR
   Retreated cases               NR                   2013-2014           NR
   Total                         265                                      88 (33.2%)
  Hamusse et al. \[[@B25]\]                                                
   New cases                     85                                       2 (2.4%)
   Retreated cases               21                   2013-2014           3 (14.3%)
   Total                         106                                      5 (4.2%)
  Mekonnen et al. \[[@B26]\]                                               
   New cases                     88                                       2 (2.3%)
   Retreated cases               36                   2014                5 (13.9%)
   Total                         124                                      7 (5.6%)

MDR-TB: multidrug-resistant tuberculosis; NR: not reported; NS: not studied.

###### 

Risk factors associated with MDR-TB in Ethiopia from 1994 to 2014.

  Risk factors                                Negative association with MDR-TB                                                                              Positive association with MDR-TB
  ------------------------------------------- ------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Previous exposure to anti-TB treatment      Biadglegne et al. \[[@B19]\]                                                                                  Agonafi et al. \[[@B12]\], Abate et al. \[[@B15]\], Abebe et al. \[[@B14]\], Nigus et al. \[[@B21]\], Mulisa et al. \[[@B24]\], Hamusse et al. \[[@B25]\], and Mekonnen et al. \[[@B26]\]
  TB history of defaulter                     NR                                                                                                            Nigus et al. \[[@B21]\]
  HIV/AIDS                                    Abate et al. \[[@B15]\] and Abebe et al. \[[@B14]\]                                                           Yimer et al. \[[@B13]\], Tessema et al. \[[@B17]\], and Mulisa et al. \[[@B24]\]
  Age                                         Yimer et al. \[[@B13]\], Abate et al. \[[@B15]\], Biadglegne et al. \[[@B19]\], and Abebe et al. \[[@B14]\]   Nigus et al. \[[@B21]\] and Mulu et al. \[[@B29]\]
  Being male                                  Yimer et al. \[[@B13]\], Abate et al. \[[@B15]\], and Abebe et al. \[[@B14]\]                                 Biadglegne et al. \[[@B19]\], Mulisa et al. \[[@B24]\], and Abate et al. \[[@B16]\]
  Occupation (farmer)                         NR                                                                                                            Mulisa et al. \[[@B24]\]
  Known TB contact history                    NR                                                                                                            Mulisa et al. \[[@B24]\]
  Nonadherence to previous TB treatment       NR                                                                                                            Shegaw \[[@B22]\]
  History of previous TB treatment            NR                                                                                                            Mulisa et al. \[[@B24]\], Shegaw \[[@B22]\], and Deressa and Demissie \[[@B28]\]
  Opportunistic infection                     NR                                                                                                            Deressa and Demissie \[[@B28]\]
  Newly treated cases                         Agonafir et al. \[[@B12]\], Abate et al. \[[@B15]\], and Abebe et al. \[[@B14]\]                              Mulu et al. \[[@B29]\]
  Lack of formal education                    NR                                                                                                            Mulisa et al. \[[@B24]\]
  Low monthly income                          NR                                                                                                            Mulu et al. \[[@B29]\]
  Cavitation on chest X-ray                   NR                                                                                                            Mulu et al. \[[@B29]\]
  History of contact with MDR-TB              NR                                                                                                            Mulu et al. \[[@B29]\]
  Rural residence                             NR                                                                                                            Mulisa et al. \[[@B24]\]
  Alcohol use                                 NR                                                                                                            Mulisa et al. \[[@B24]\] and Mulu et al. \[[@B29]\]
  Chat chew                                   NR                                                                                                            Mulisa et al. \[[@B24]\]
  Previous unfavorable TB treatment outcome   NR                                                                                                            Mulisa et al. \[[@B24]\]
  Previous history of TB treatment failure    NR                                                                                                            Mulu et al. \[[@B29]\]
  Primary education                           NR                                                                                                            Deressa and Demissie \[[@B28]\]
  Unemployment                                NR                                                                                                            Deressa and Demissie \[[@B28]\]
  Long distance to the healthcare facility    NR                                                                                                            Deressa and Demissie \[[@B28]\]

NR: not reported.
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